Metrics of salbutamol use as predictors of future adverse outcomes in asthma

Clinical and Experimental Allergy

Volumn 43, Issue 10, 2013, Pages 1144-1151

  Patel, M ^a,b,c   Pilcher, J ^a,b   Reddel, H K ^d   Pritchard, A ^a   Corin, A ^e   Helm, C ^e   Tofield, C ^e   Shaw, D ^c   Black, P ^f   Weatherall, M ^b,g   Beasley, R ^a,b,g  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^e CentralMed   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Beta agonist; Budesonide formoterol; Control; Electronic monitoring; Exacerbations; Risk

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; SALBUTAMOL;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; ASTHMA; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABUSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OPEN STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR;

BETA-AGONIST; BUDESONIDE/FORMOTEROL; CONTROL; ELECTRONIC MONITORING; EXACERBATIONS; RISK;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALBUTEROL; ASTHMA; DRUG OVERDOSE; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROGNOSIS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84884694448     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12166     Document Type: Article

References (30)

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA). Available at www.ginasthma.org. Date last updated: 2012 (Accessed 16 June 2013).
2. National Heart Lung and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. 2007. Available at http://www.nhlbi.nih.gov/guidelines/asthma/index.htm (Accessed 21 January 2013).
3. Taylor DR, Bateman ED, Boulet LP et al. A new perspective on concepts of asthma severity and control. Eur Respir J 2008; 32:545-54.
4. Eisner MD, Lieu TA, Chi F et al. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma. Eur Respir J 2001; 17:233-40.
5. Windom HH, Burgess CD, Crane J, Pearce N, Kwong T, Beasley R. The self-administration of inhaled beta agonist drugs during severe asthma. N Z Med J 1990; 103:205-7.
6. Spitzer W, Suissa S, Ernst P et al. The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 1992; 326:501-6.
7. Suissa S, Blais L, Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994; 7:1602-9.
8. Beasley R, Pearce N, Crane J, Burgess C. Beta-agonists: what is the evidence that their use increases the risk of asthma morbidity and mortality? J Allergy Clin Immunol 1999; 104:S18-30.
9. Patel M, Pilcher J, Pritchard A et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013; 1:32-42.
10. Patel M, Pilcher J, Chan A, Perrin K, Black P, Beasley R. Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. J Allergy Clin Immunol 2012; 130:1420-2.
11. Patel M, Pilcher J, Travers J et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. J Allergy Clin Immunol: In Practice 2013; 1:83-91.
12. Rand CS, Wise RA, Nides M et al. Metered-dose inhaler adherence in a clinical trial. Am Rev Respir Dis 1992; 146:1559-64.
13. Reddel HK, Taylor DR, Bateman ED et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009; 180:59-99.
14. Juniper EF, Bousquet J, Abetz L, Bateman ED. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006; 100:616-21.
15. Juniper EF, Svensson K, Mork AC, Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005; 99:553-8.
16. Juniper EF, O'Byrne PM, Guyatt GH, Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902-7.
17. Holt S, Masoli M, Beasley R. The use of the self-management plan system of care in adult asthma. Prim Care Respir J 2004; 13:19-27.
18. Thamrin C, Zindel J, Nydegger R et al. Predicting future risk of asthma exacerbations using individual conditional probabilities. J Allergy Clin Immunol 2011; 127:1494-502, e1493.
19. McCoy K, Shade DM, Irvin CG et al. Predicting episodes of poor asthma control in treated patients with asthma. J Allergy Clin Immunol 2006; 118: 1226-33.
20. Kitch BT, Paltiel AD, Kuntz KM et al. A single measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004; 126: 1875-82.
21. O'Connor RD, Bleecker ER, Long A et al. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data. J Asthma 2010; 47:422-8.
22. Zeiger RS, Yegin A, Simons FE et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012; 108:81-7.
23. Gelb AF, Taylor CF, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest 2006; 129:1492-9.
24. Hessel PA, Mitchell I, Tough S et al. Risk factors for death from asthma. Prairie Provinces Asthma Study Group. Ann Allergy Asthma Immunol 1999; 83:362-8.
25. Ulrik CS, Frederiksen J. Mortality and markers of risk of asthma death among 1, 075 outpatients with asthma. Chest 1995; 108:10-5.
26. Haldar P, Pavord ID, Shaw DE et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218-24.
27. Schatz M, Zeiger RS, Vollmer WM et al. The controller-to-total asthma medication ratio is associated with patient-centered as well as utilization outcomes. Chest 2006; 130:43-50.
28. Bremner P, Woodman K, Burgess C et al. A comparison of the cardiovascular and metabolic effects of formoterol, salbutamol and fenoterol. Eur Respir J 1993; 6:204-10.
29. Hoskins G, Williams B, Jackson C, Norman P, Donnan P. Patient, practice and organisational influences on asthma control: observational data from a national study on primary care in the United Kingdom. Int J Nurs Stud 2012; 49:596-609.
30. Boulet LP, Vervloet D, Magar Y, Foster JM. Adherence: the goal to control asthma. Clin Chest Med 2012; 33:405-17.